Hot flashes are characteristic symptoms of menopausal women, though could result from other medical conditions too. The symptoms include sudden sensation of intense warmth spreading over body lasting for several minutes leading to sweating, red flush, and palpitations. The severity of these symptoms can vary from woman to woman. Other causes of hot flashes include breast and prostate cancer treatments. Hormone replacement therapy (HRT) is the most effective treatment for menopausal hot flashes. However, long term HRT has an increased risk of breast cancer and risk associated with increasing age such as stroke, blood clots, and other health related problems. Other therapies include intake of vitamin E supplements and anti-depressants along with various complementary therapies. In the U.S. and other developed countries approximately 70% of menopausal women experience hot flashes that can last for several years. According to a publication by Harvard Medical School, on average, hot flashes can last for about 7 years to 11 years.
The menopausal hot flashes market has been segmented on the basis of product, and geography. The product segment has been further segmented into hormonal (estrogen, progestin and combination) and non-hormonal products. Estrogen accounted for the largest share of the global menopausal hot flashes market in terms of revenue as well as prescription volume. Estrogen position in hot flashes treatment market is unchallenged as none of the other available drugs is as effective as estrogen. Some of the recent studies show that non-estrogen drugs may have up to 70% of the effectiveness of estrogen therapy when treating hot flashes. The hormonal hot flashes market has experienced sluggish growth over the past decade. However, it is expected to witness a substantial change between 2015 and 2023. Several market-leading therapies, including Vivelle-Dot (estrogen) by Novartis and Premarin (conjugated estrogens) by Pfizer have lost patent and few more drugs would go off-patent in the next few years. Furthermore, a number of vaginal patches, oral estrogens, and vaginal creams would lose exclusivity, leading to abundance of cheaper generic options in the market. However, with the elevated risk of cancer (womb) in certain group of population is the major restrain for this therapy, especially in the developed world. Moreover, the non-hormonal segment is likely to expand at the highest rate from 2015 to 2023, owing to it being considered as a best option to avoid the increased risk of cancer in certain high risk populations. Non-hormonal therapy includes antidepressants and other prescription drugs that offer relief for some women. Brisdelle is the only non-hormonal medication approved by the FDA for treating hot flashes. Nonetheless, it is expensive as compared to generic formulations, rendering it a limiting factor for its future market penetration.
On the basis of geography, the menopausal hot flashes market has segmented into: North America, Europe, Asia Pacific, Latin America, the Middle East and North Africa (MENA), and Rest of the World (RoW). North America was the largest regional market for menopausal hot flashes treatment, followed by Europe in 2014. The dominance of these two regions is attributed to the presence of large population of menopausal women experiencing hot flashes than any other part of the world. Furthermore, increasing demand for non-hormonal drugs is likely to fuel market growth in this region from 2015 to 2023. Asia Pacific is anticipated to witness the fastest growth rate during the forecast period. In addition to large population pool, rising disposable income, rapid urbanization, and increase in women’s health expenditure across the region support market growth in the region. The menopausal hot flashes market in Rest of the World offers large opportunities and is projected to expand at a decent rate in the next few years. Driving factors for the region include improving health care infrastructure and growing menopause women in this region. According to a review article published in 2014, the number of women approaching menopause in Brazil is increasing. Of the 30 million women in Brazil, around 32% are aged between 35 and 65 years. This has created an ample of opportunities for both domestic and international companies.
The menopausal hot flashes market is highly fragmented due to the presence of large number of small and medium generic manufacturing companies across the world. Top ten manufacturers accounted for around 44.5% of the market in 2014. Key players operating in the market include Allergan plc, Bayer AG, Hisamitsu Pharmaceutical Co., Inc., Merck & Co., Inc., Novartis International AG, Novo Nordisk Corporation, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.